Corinthian Technologies Incorporated

Mapping the breakthroughs that reshape medicine.

Deep research at the intersection of bioscience, systems thinking, and science policy — where the next paradigm shift comes from, and why it happens when it does.

CAR-T therapy CRISPR Autoimmune disease Systems thinking Science policy

Blog

Long-form analysis of bioscience breakthroughs, systems thinking, and science policy.

eBooks

In-depth research guides — free to read, built to last.

About

The researcher, writer, and systems thinker behind this work.

01
Bioscience
CAR-T for autoimmune disease: what Erlangen proved and what comes next
University Hospital Erlangen's CAR-T trials in lupus, myositis, and systemic sclerosis didn't just show remission — they rewrote what remission means for autoimmune patients.
BioscienceSystems
02
Bioscience
The first personalized CRISPR therapy: how CHOP and UPenn pulled it off
In 2025, a child with a rare metabolic disorder became the first person treated with a bespoke CRISPR gene therapy designed for their specific mutation. Here is how it happened.
BiosciencePolicy
03
Systems thinking
What conditions allow scientific breakthroughs to occur?
A systemic framework for understanding why certain institutions, cities, and moments produce paradigm shifts — and most don't. Loops, leverage points, and the structures behind discovery.
SystemsPolicy
04
Policy
The regulatory gap between what gene therapy can do and what policy allows
As personalized therapies become technically feasible, the frameworks governing their approval were built for a different era. Something has to give.
PolicyBioscience
← Back to blog
The Breakthrough Conditions Framework

The Breakthrough Conditions Framework

A systemic analysis of what makes scientific breakthroughs possible — institutions, funding, talent, and timing.

CAR-T and the Future of Autoimmune Treatment

CAR-T and autoimmune treatment

Deep dive into CAR-T cell therapy for autoimmune disease — the science, the trials, and what comes next.

CRISPR at the Frontier: Policy, Ethics, and the Personalized Medicine Era

CRISPR at the frontier

From base editing to bespoke therapies — how CRISPR is outpacing the regulatory frameworks built to govern it.

← Back to eBooks
CT
Corinthian Technologies
Founder · Researcher · Writer

Researching the conditions that produce scientific change.

I founded Corinthian Technologies Incorporated to document and analyze bioscience breakthroughs — not just what happened, but why it happened here, now, and not somewhere else.

My work sits at the intersection of life sciences, systems thinking, and science policy. I'm particularly focused on autoimmune disorders, gene therapy, and the institutional structures that either accelerate or obstruct breakthrough science.

Current projects include a deep analysis of CAR-T cell therapy for autoimmune disease (University Hospital Erlangen), documentation of the first personalized CRISPR therapy case (CHOP/UPenn, 2025), and a systemic framework for understanding breakthrough conditions.

Bioscience research Systems thinking Science policy CAR-T therapy CRISPR / gene editing Autoimmune disease Long-form writing
2025

First personalized CRISPR therapy documented

CHOP/UPenn case — the first bespoke gene therapy built for a single patient's mutation.

2024

CAR-T autoimmune research begins

Deep dive into University Hospital Erlangen's landmark trials in lupus and systemic sclerosis.

2023

Corinthian Technologies Incorporated founded

Launched with a focus on bioscience documentation and systemic analysis.